<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbl2" position="float">
 <label>Table 2</label>
 <caption>
  <p>Adverse events and therapeutic compliance.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="3">Grade 3–4 adverse events</th>
    <th colspan="2">ICT/CCRT
     <hr/>
    </th>
    <th>CCRT
     <hr/>
    </th>
   </tr>
   <tr>
    <th>ICT (n = 70)
     <hr/>
    </th>
    <th>CCRT (n = 58)
     <hr/>
    </th>
    <th>CCRT (n = 66)
     <hr/>
    </th>
   </tr>
   <tr>
    <th>n (%)</th>
    <th>n (%)</th>
    <th>n (%)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Neutropenia</td>
    <td>0 (0)</td>
    <td>7 (12.0)</td>
    <td>8 (12.1)</td>
   </tr>
   <tr>
    <td>Anemia</td>
    <td>5 (7.1)</td>
    <td>19 (32.8)</td>
    <td>7 (10.6)</td>
   </tr>
   <tr>
    <td>Thrombocytopenia</td>
    <td>1 (1.4)</td>
    <td>2 (3.4)</td>
    <td>2 (3.0)</td>
   </tr>
   <tr>
    <td>Emesis</td>
    <td>1 (1.4)</td>
    <td>4 (6.9)</td>
    <td>0 (0)</td>
   </tr>
   <tr>
    <td>Mucositis</td>
    <td>0 (0)</td>
    <td>41 (70.7)</td>
    <td>39 (59.1)</td>
   </tr>
   <tr>
    <td>Dermatitis</td>
    <td>1 (1.4)</td>
    <td>7 (12.0)</td>
    <td>10 (15.1)</td>
   </tr>
   <tr>
    <td>Diarrhea</td>
    <td>10 (14.3)</td>
    <td>0 (0)</td>
    <td>2 (3.0)</td>
   </tr>
   <tr>
    <td>Renal insufficiency</td>
    <td>0 (0)</td>
    <td>0 (0)</td>
    <td>1 (1.5)</td>
   </tr>
   <tr>
    <td>Liver dysfunction</td>
    <td>0 (0)</td>
    <td>1 (1.7)</td>
    <td>1 (1.5)</td>
   </tr>
   <tr>
    <td colspan="4">Compliance during CCRT</td>
   </tr>
   <tr>
    <td>Tube feeding</td>
    <td/>
    <td>36 (62)</td>
    <td>43 (65)</td>
   </tr>
   <tr>
    <td>RT dose: median (range) (Gy)</td>
    <td/>
    <td>72 (12–76)</td>
    <td>72 (24–76)</td>
   </tr>
   <tr>
    <td>RT dose &lt;70 Gy</td>
    <td/>
    <td>7 (12)</td>
    <td>8 (12)</td>
   </tr>
   <tr>
    <td>RT duration: median (range) (days)</td>
    <td/>
    <td>52 (7–90)</td>
    <td>53 (19–150)</td>
   </tr>
   <tr>
    <td colspan="4">Total dose of cisplatin in CCRT</td>
   </tr>
   <tr>
    <td> &lt;150 mg/m
     <sup>2</sup>
    </td>
    <td/>
    <td>36 (46.8)</td>
    <td>12 (16.2)</td>
   </tr>
   <tr>
    <td>Hospitalization</td>
    <td/>
    <td>15 (25.8)</td>
    <td>20 (30.3)</td>
   </tr>
   <tr>
    <td>Body weight loss: mean (range)</td>
    <td/>
    <td>8.9% (0–30%)</td>
    <td>7.6% (0–20%)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Abbreviations: CCRT: concurrent chemoradiotherapy; ICT/CCRT: induction chemotherapy followed by concurrent chemoradiotherapy.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
